Oligodendroglial tumors: Diagnostic and molecular pathology

Seminars in Diagnostic Pathology

Volumn 27, Issue 2, 2010, Pages 136-145

  Rodriguez, Fausto J ^a   Giannini, Caterina ^a  

^a MAYO CLINIC   (United States)

Author keywords

Brain tumor; Grading; Oligoastrocytoma; Oligodendroglioma

Indexed keywords

CHROMOGRANIN; CHROMOSOME PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; PROTEIN P53; PROTEIN S 100; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR SOX10; TYROSINE KINASE RECEPTOR; TUMOR MARKER;

ARTICLE; ASTROCYTOMA; CANCER GRADING; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME ANALYSIS; CHROMOSOME DELETION; CLINICAL FEATURE; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; MOLECULAR BIOLOGY; NEUROEPITHELIOMA; NEUROIMAGING; NEUROPATHOLOGY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROGNOSIS; WORLD HEALTH ORGANIZATION; BRAIN NEOPLASMS; CHROMOSOME 1; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; GLIOMA; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES;

ASTROCYTOMA; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CYTOGENETIC ANALYSIS; DIAGNOSIS, DIFFERENTIAL; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 77955234721     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2010.05.001     Document Type: Article

References (74)

1. Kros J.M., Gorlia T., Kouwenhoven M.C., et al. Panel review of anaplastic oligodendroglioma from European Organization for Research and Treatment of Cancer Trial 26951: Assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 2007, 66:545-551.
2. Coons S.W., Johnson P.C., Scheithauer B.W., et al. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997, 79:1381-1393.
3. Bailey P., Cushing H. A Classification of the Tumors of the Glioma Group on a Histogenetic Basis with a Correlated Study of Prognosis 1926, Lippincott, Philadelphia.
4. Bailey P., Bucy P.C. Oligodendrogliomas of the brain. J Pathol Bacteriol 1929, 32:735.
5. Burger P.C. What is an oligodendroglioma?. Brain Pathol 2002, 12:257-259.
6. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
7. Louis D., Ohgaki H., Wiestler O. WHO Classification of Tumours of the Central Nervous System 2007, International Agency for Research on Cancer, Lyon, France.
8. Rossi S., Rodriguez F.J., Mota R.A., et al. Primary leptomeningeal oligodendroglioma with documented progression to anaplasia and t(1;19)(q10;p10) in a child. Acta Neuropathol 2009, 118:575-577.
9. Osborne A.G. Diagnostic Imaging Brain 2004, Amirsys, Salt Lake City, UT.
10. Megyesi J.F., Kachur E., Lee D.H., et al. Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 2004, 10:4303-4306.
11. Eoli M., Bissola L., Bruzzone M.G., et al. Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 2006, 119:84-90.
12. Jentoft M., Giannini C., Rossi S., et al. Oligodendroglial tumors with desmoplastic parenchymal response: A Case series. Lab Invest 2010, 90:377A.
13. Schiffer D., Cravioto H., Giordana M.T., et al. Is polar spongioblastoma a tumor entity?. J Neurosurg 1993, 78:587-591.
14. Perry A., Scheithauer B.W., Macaulay R.J., et al. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 2002, 61:947-955.
15. Rodriguez F.J., Scheithauer B.W., Jenkins R., et al. Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): A clinicopathologic study. Am J Surg Pathol 2007, 31:351-362.
16. Giannini C., Scheithauer B.W., Weaver A.L., et al. Oligodendrogliomas: Reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol 2001, 60:248-262.
17. Daumas-Duport C., Tucker M.L., Kolles H., et al. Oligodendrogliomas. part II: A new grading system based on morphological and imaging criteria. J Neuro Oncol 1997, 34:61-78.
18. Daumas-Duport C., Varlet P., Tucker M.L., et al. Oligodendrogliomas. part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases. J Neuro Oncol 1997, 34:37-59.
19. Miller C.R., Dunham C.P., Scheithauer B.W. Significance of necrosis in grading of oligodendroglial neoplasms: A clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol 2006, 24:5419-5426.
20. Scheithauer B.W., Fuller G.N., vandenBerg S.R. The 2007 WHO classification of tumors of the nervous system: Controversies in surgical neuropathology. Brain Pathol 2008, 18:307-316.
21. Kouwenhoven M.C., Gorlia T., Kros J.M., et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951. Neuro Oncol 2009, 11:737-746.
22. Lu Q.R., Park J.K., Noll E., et al. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Proc Natl Acad Sci U S A 2001, 98:10851-10856.
23. Ligon K.L., Alberta J.A., Kho A.T., et al. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. J Neuropathol Exp Neurol 2004, 63:499-509.
24. Ueki K., Nishikawa R., Nakazato Y., et al. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors. Clin Cancer Res 2002, 8:196-201.
25. Vyberg M., Ulhoi B.P., Teglbjaerg P.S. Neuronal features of oligodendrogliomas: An ultrastructural and immunohistochemical study. Histopathology 2007, 50:887-896.
26. Wharton S.B., Chan K.K., Hamilton F.A. Expression of neuronal markers in oligodendrogliomas: An immunohistochemical study. Neuropathol Appl Neurobiol 1998, 24:302-308.
27. Senetta R., Trevisan E., Rudà R., et al. Caveolin 1 expression independently predicts shorter survival in oligodendrogliomas. J Neuropathol Exp Neurol 2009, 68:425-431.
28. Daumas-Duport C., Scheithauer B.W., Chodkiewicz J.P., et al. Dysembryoplastic neuroepithelial tumor: A surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases. Neurosurgery 1988, 23:545-556.
29. Ray W.Z., Blackburn S.L., Casavilca-Zambrano S., et al. Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: A report of 5 cases and review of the literature. J Neuro Oncol 2009, 94:283-292.
30. Brat D.J., Scheithauer B.W., Eberhart C.G. Extraventricular neurocytomas: Pathologic features and clinical outcome. Am J Surg Pathol 2001, 25:1252-1260.
31. Giangaspero F., Cenacchi G., Losi L., et al. Extraventricular neoplasms with neurocytoma features. A clinicopathological study of 11 cases. Am J Surg Pathol 1997, 21:206-212.
32. Perry A., Fuller C.E., Banerjee R., et al. Ancillary FISH analysis for 1p and 19q status: Preliminary observations in 287 gliomas and oligodendroglioma mimics. Front Biosci 2003, 8:a1-a9.
33. Rodriguez F.J., Mota R.A., Scheithauer B.W., et al. Interphase cytogenetics for 1p19q and t(1;19)(q10;p10) may distinguish prognostically relevant subgroups in extraventricular neurocytoma. Brain Pathol 2009, 19:623-629.
34. Leenstra J.L., Rodriguez F.J., Frechette C.M., et al. Central neurocytoma: Management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys 2007, 67:1145-1154.
35. Kawano N., Yada K., Aihara M. Oligodendroglioma-like cells (clear cells) in ependymoma. Acta Neuropathol 1983, 62:141-144.
36. Perry A., Aldape K.D., George D.H. Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004, 101:2318-2326.
37. Jenkins R.B., Kimmel D.W., Moertel C.A., et al. A cytogenetic study of 53 human gliomas. Cancer Genet Cytogenet 1989, 39:253-279.
38. Ritland S.R., Ganju V., Jenkins R.B. Region-specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma. Genes Chromosomes Cancer 1995, 12:277-282.
39. Reifenberger J., Reifenberger G., Liu L., et al. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994, 145:1175-1190.
40. Smith J.S., Perry A., Borell T.J., et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000, 18:636-645.
41. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998, 90:1473-1479.
42. Kaloshi G., Benouaich-Amiel A., Diakite F., et al. Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome. Neurology 2007, 68:1831-1836.
43. Nigro J.M., Takahashi M.A., Ginzinger D.G., et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 2001, 158:1253-1262.
44. Giannini C., Burger P.C., Berkey B.A., et al. Anaplastic oligodendroglial tumors: Refining the correlation among histopathology, 1p 19q deletion and clinical outcome in InterGroup Radiation Therapy Oncology Group trial 9402. Brain Pathol 2008, 18:360-369.
45. Kreiger P.A., Okada Y., Simon S., et al. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas. Acta Neuropathol 2005, 109:387-392.
46. Raghavan R., Balani J., Perry A., et al. Pediatric oligodendrogliomas: A study of molecular alterations on 1p and 19q using fluorescence in situ hybridization. J Neuropathol Exp Neurol 2003, 62:530-537.
47. Schniederjan M.J., Janss A.J., Mazewski C. Pediatric oligodendrogliomas: Is 1p19q deletion more common that previously thought?. Lab Invest 2010, 90:381A.
48. Griffin C.A., Burger P., Morsberger L., et al. Identification of der(1; 19) (q10; p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol 2006, 65:988-994.
49. Jenkins R.B., Blair H., Ballman K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006, 66:9852-9861.
50. von Deimling A., Louis D.N., von Ammon K., et al. Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. Cancer Res 1992, 52:4277-4279.
51. Snuderl M., Eichler A.F., Ligon K.L., et al. Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009, 15:6430-6437.
52. McDonald J.M., See S.J., Tremont I.W., et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005, 104:1468-1477.
53. Smith J.S., Alderete B., Minn Y., et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene 1999, 18:4144-4152.
54. Barbashina V., Salazar P., Holland E.C., et al. Allelic losses at 1p36 and 19q13 in gliomas: Correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005, 11:1119-1128.
55. Husemann K., Wolter M., Büschges R., et al. Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors. J Neuropathol Exp Neurol 1999, 58:1041-1050.
56. McDonald J.M., Dunlap S., Cogdell D., et al. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. Cancer Biol Ther 2006, 5:300-304.
57. Dong S., Pang J.C., Hu J., et al. Transcriptional inactivation of TP73 expression in oligodendroglial tumors. Int J Cancer 2002, 98:370-375.
58. Ngo T.T., Peng T., Liang X.J., et al. The 1p-encoded protein stathmin and resistance of malignant gliomas to nitrosoureas. J Natl Cancer Inst 2007, 99:639-652.
59. McDonald J.M., Dunmire V., Taylor E., et al. Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss. Mol Cancer 2005, 4:35.
60. Tews B., Roerig P., Hartmann C., et al. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q. Oncogene 2007, 26:5010-5016.
61. Riemenschneider M.J., Reifenberger J., Reifenberger G. Frequent biallelic inactivation and transcriptional silencing of the DIRAS3 gene at 1p31 in oligodendroglial tumors with 1p loss. Int J Cancer 2008, 122:2503-2510.
62. Smith J.S., Tachibana I., Lee H.K., et al. Mapping of the chromosome 19 q-arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers. Genes Chromosomes Cancer 2000, 29:16-25.
63. Smith J.S., Tachibana I., Pohl U., et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 2000, 64:44-50.
64. Alaminos M., Dávalos V., Ropero S., et al. EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res 2005, 65:2565-2571.
65. Yang P., Kollmeyer T.M., Buckner K., et al. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer 2005, 103:2363-2372.
66. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
67. Hartmann C., Meyer J., Balss J., et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol 2009, 118:469-474.
68. Koschny R., Koschny T., Froster U.G., et al. Comparative genomic hybridization in glioma: A meta-analysis of 509 cases. Cancer Genet Cytogenet 2002, 135:147-159.
69. Kros J.M., van Run P.R., Alers J.C., et al. Genetic aberrations in oligodendroglial tumours: An analysis using comparative genomic hybridization (CGH). J Pathol 1999, 188:282-288.
70. Kitange G., Misra A., Law M., et al. Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas. Genes Chromosomes Cancer 2005, 42:68-77.
71. Smith J.S., Wang X.Y., Qian J., et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 2000, 59:495-503.
72. Mollemann M., Wolter M., Felsberg J., et al. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005, 113:379-385.
73. Cairncross G., Cairncross G., Berkey B., et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: InterGroup Radiation Therapy Oncology Group trial 9402. J Clin Oncol 2006, 24:2707-2714.
74. van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: A randomized European Organization for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006, 24:2715-2722.